Development of a Novel Loop-Mediated Isothermal Amplification Method to Detect Guiana Extended-Spectrum (GES) \(\beta\)-Lactamase Genes in \textit{Pseudomonas aeruginosa}

Chika Takano  
\textit{Nihon University}

Mitsuko Seki  
\textit{Nihon University}

Dong Wook Kim  
\textit{Hanyang University}

Humphrey Gardner  
\textit{Evelo Biosciences}

Robert E. McLaughlin  
\textit{Institute for Life Science Entrepreneurship}

Recommended Citation
Takano C, Seki M, Kim DW, Gardner H, McLaughlin RE, Kilgore PE, Kumasaka K and Hayakawa S (2019) Development of a Novel Loop-Mediated Isothermal Amplification Method to Detect Guiana Extended-Spectrum (GES) \(\beta\)-Lactamase Genes in \textit{Pseudomonas aeruginosa}. \textit{Front. Microbiol.} 10:25. doi: 10.3389/fmicb.2019.00025

This Article is brought to you for free and open access by the Eugene Applebaum College of Pharmacy and Health Sciences at DigitalCommons@WayneState. It has been accepted for inclusion in Department of Pharmacy Practice by an authorized administrator of DigitalCommons@WayneState.
Authors
Chika Takano, Mitsuko Seki, Dong Wook Kim, Humphrey Gardner, Robert E. McLaughlin, Paul E. Kilgore, Kazunari Kumasaka, and Satoshi Hayakawa
Development of a Novel Loop-Mediated Isothermal Amplification Method to Detect Guiana Extended-Spectrum (GES) β-Lactamase Genes in Pseudomonas aeruginosa

Chika Takano1, Mitsuko Seki1,2*, Dong Wook Kim3,4*, Humphrey Gardner5, Robert E. McLaughlin6, Paul E. Kilgore7, Kazunari Kumasaka8 and Satoshi Hayakawa1

1 Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan, 2 Division of Pediatric Dentistry, Meikai University School of Dentistry, Sakado, Japan, 3 Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, South Korea, 4 Institute of Pharmacological Research, Hanyang University, Ansan, South Korea, 5 Evelo Biosciences, Cambridge, MA, United States, 6 Institute for Life Science Entrepreneurship, Union, NJ, United States, 7 Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, United States, 8 Department of Laboratory Medicine, Ageo Central General Hospital, Ageo, Japan

Infections caused by multidrug-resistant Pseudomonas aeruginosa in hospitalized patients are often fatal, and nosocomial infections caused by Guiana extended-spectrum (GES) β-lactamase-producing strains are of growing concern. Several genotypes of the GES β-lactamase gene (blaGES) include a single missense mutation, a change from G to A at nucleotide position 493 (G493A) that changes glycine to serine; the mutant enzyme exhibits carbapenemase activity. Rapid and reliable identification of drug-resistance is important in clinical settings; however, culture methods remain the gold standard. Conventional and real-time PCR cannot identify carbapenemase-producing genotypes, and direct DNA sequencing is essential. We established a novel loop-mediated isothermal amplification (LAMP) method to detect various genotypes of blaGES and another LAMP method to discriminate carbapenemase genotypes of blaGES. We evaluated the two assays using clinical P. aeruginosa strains. Two primer sets targeting blaGES (GES-LAMP) and the point mutation (Carba-GES-LAMP) were designed and evaluated for specificity and sensitivity. The detection limit of the GES-LAMP method was assessed using purified DNA and DNA-spiked clinical samples (urine, sputum, and blood). To determine the clinical usefulness of the methods, we used different (genotypically and phenotypically) P. aeruginosa clinical isolates, collected from diverse geographical locations between 2003 and 2012. The novel LAMP assay targeting blaGES was highly specific. The detection limit was 10 DNA copies per reaction; the assay was 10-fold more sensitive than conventional PCR. The LAMP assay detected blaGES with high sensitivity in all DNA-spiked samples; PCR did not detect blaGES in blood samples. The GES-LAMP method correctly detected the 5 isolates containing...
INTRODUCTION

Multidrug-resistant bacteria have spread worldwide and become a major clinical concern and public health issue as well. Invasive infection by *Pseudomonas aeruginosa* is often fatal in the absence of appropriate antibiotic treatment (Miyoshi-Akiyama et al., 2017). As β-lactamase genes are plasmid-borne, a failure to treat drug-resistant bacteria may trigger nosocomial infections. Of the various β-lactamase genes, Guiana extended-spectrum (GES) β-lactamase has become of increasing concern (Poirel et al., 2012). GES was first described in 2000 in French Guiana (Poirel et al., 2000) and is an Amber class A extended-spectrum β-lactamase. However, certain variants (GES-4, -5, -6, -14, -15, -16, -18, -20, and -24) feature a single missense mutation at nucleotide position 493 (G493A) that changes glycine 165 to serine (Gly165Ser), which was previously reported as Gly170Ser (Bebrone et al., 2013). The resulting mutant enzyme exhibits carbapenemase activity (Bonnin et al., 2017). In Japan, GES-4 and GES-5 carbapenemase-producing *P. aeruginosa* have caused severe hospital-acquired infections (Kanayama et al., 2016; Yamasaki et al., 2017). Reports of GES-type enzymes remain rare but are steadily increasing (Naas et al., 2016).

Rapid and reliable identification of drug-resistance is essential to ensure that antibiotic use is appropriate. Conventional culture remains the gold standard for assessing antibiotic resistance despite being time-consuming, requiring sophisticated laboratory equipment and quality-control, and yielding ambiguous outcomes. Furthermore, the number of inoculated bacteria affect the drug minimum inhibitory concentration (MIC) (Bratu et al., 2005). Conventional PCR-based assays can detect β-lactamase genes but require well-equipped laboratories. Moreover, neither conventional PCR nor real-time PCR can identify carbapenemase-producing genotypes, and direct DNA sequencing is essential to do so (de Oliveira et al., 2017).

Loop-mediated isothermal amplification (LAMP) methods are becoming increasingly popular due to their relative simplicity and accuracy. The unique priming mechanism allows rapid and specific DNA amplification (Notomi et al., 2000), with no requirement for expensive equipment or a sophisticated laboratory. LAMP is a convenient and inexpensive alternative to PCR in terms of point-of-care testing (POCT). Here, we established two LAMP methods to detect the GES β-lactamase gene (*bla*<sub>GES</sub>, GES-LAMP) and carbapenemase genotypes (Carba-GES-LAMP) and applied the two assays to evaluate characterized (both genotypically and phenotypically) clinical *P. aeruginosa* strains from diverse geographical locations collected between 2003 and 2012 (Kos et al., 2015).

### MATERIALS AND METHODS

#### Bacterial Strains

A total of 22 bacterial strains including 8 standard strains (Table 1) and 14 clinical *P. aeruginosa* strains (Table 2) were used to evaluate the LAMP methods. The eight standard strains included six kinds of genotypes of β-lactamase producers (KPC, NDM, VIM, IMP, OXA, and GES): two *Klebsiella pneumoniae*, one *Escherichia coli*, four *P. aeruginosa*, and one *Acinetobacter baumannii* provided by AstraZeneca (Waltham, MA, United States). Genomic DNA was extracted using the Maxwell 16-cell DNA purification kit (Promega, Madison, WI, United States). DNA concentrations were measured using the NanoDrop 1000 (Thermo Fisher Scientific Inc., Waltham, MA, United States). Genome copy numbers were calculated based on genome sizes of 6.5 Mbp for *P. aeruginosa* (PB369; GenBank accession number, CP025049.1), 5.4 Mbp for *K. pneumoniae* (Kp52.145; GenBank accession number, FO834906.1), 5.2 Mbp for *E. coli* (CFT073; GenBank accession number, AE014075.1), and 4.5 Mbp for *A. baumannii* (XH901; GenBank accession number, NZ_CP018259.1). Each DNA sample was normalized to the same concentration and used to evaluate assay specificity. To validate *bla*<sub>GES</sub> detection limits, we used genomic DNA from the *P. aeruginosa* strain ARC3917. Serial 10-fold-diluted DNA samples (10<sup>5</sup>, 10<sup>4</sup>, 10<sup>3</sup>, 10<sup>2</sup>, 10, and 1 genome copies) were amplified by LAMP and the results were compared with those from PCR assays. To confirm reproducibility, triplicate tests were performed over a 3-day period.

#### TABLE 1 | Reactivities and specificities of PCR and LAMP assays detecting *bla*<sub>GES</sub>.

| Strain ID | Species                         | Genotype | PCR<sup>a</sup> | GES-LAMP<sup>b</sup> |
|-----------|---------------------------------|----------|-----------------|-----------------------|
| ARC2790   | Acinetobacter baumannii         | IMP-1    | (−)             | (−)                   |
| ARC2945   | Klebsiella pneumoniae           | KPC-2    | (−)             | (−)                   |
| ARC3471   | Pseudomonas aeruginosa          | VIM-2    | (−)             | (−)                   |
| ARC3475   | Pseudomonas aeruginosa          | OXA-48   | (−)             | (−)                   |
| ARC3800   | Escherichia coli                | NDM-1    | (−)             | (−)                   |
| ARC3802   | Klebsiella pneumoniae           | NDM-1    | (−)             | (−)                   |
| ARC3917   | Pseudomonas aeruginosa          | GES-1    | (+)             | (+)                   |
| ARC3936   | Pseudomonas aeruginosa          | VIM-7    | (−)             | (−)                   |

<sup>a</sup>PCR results obtained via electrophoretic analysis; <sup>b</sup>LAMP results determined via Loopamp real-time turbidimetry and the naked eye. <sup>c</sup>(−), negative; (+), positive.

---

Keywords: *bla*<sub>GES</sub>, β-lactamase, point mutation, carbapenemase, loop-mediated isothermal amplification, *Pseudomonas aeruginosa*
We targeted the LAMP Primer Design assay. Single nucleotide mutation to the 5′ end, followed by the addition of two mutations in the second (G to C) and fifth (A to T) positions from the 5′ end. Other primers were designed using Primer Explorer V5 software (Table 3).

### Clinical P. aeruginosa Strains

Fourteen clinical P. aeruginosa strains including five blaGES segments (GES-1, -5, -7, -9, and -19/20-like) were randomly selected from 388 strains with previously reported genotypes and phenotypes (Kos et al., 2015; Table 2) isolated from diverse geographical locations (Colombia, India, Spain, France, Greece, Germany, Argentina, Croatia, China, Brazil, Mexico, and the Philippines) between 2003 and 2012. Genomic DNA was extracted using the Maxwell 16-cell DNA purification kit (Promega). Whole-genome sequences were analyzed using the HiSeq 2000 or MiSeq platforms (Illumina, San Diego, CA, United States). Susceptibility to meropenem was explored using frozen Trek-Sensititre custom plates (Thermo Fisher Scientific Inc.) following the guidelines of the Clinical and Laboratory Standards Institute (2012). The results of meropenem MIC are listed in Table 2. We used genomic DNA from P. aeruginosa strain AZPAE4948 to evaluate the LAMP assay.

### LAMP Primer Design

We targeted the blaGES gene (GES-1; GenBank accession number, AF355189.1; Supplementary Figure S1) using primers designed by Primer Explorer V5 software (FUJITSU, 2016). The LAMP primers included two outer primers (F3 and B3), a forward inner primer (FIP), a backward inner primer (BIP), and loop primers (LF and LB) (Table 3). In addition, we developed primers targeting the G493A mutation of blaGES (GES-5; GenBank accession number, EF190326.1; Supplementary Figure S1) using an amplification-refractory mutation system (ARMS) (Newton et al., 1989; Ikeda et al., 2007). The BIP featured the addition of a single nucleotide mutation to the 5′-end, followed by the addition of two mutations in the second (G to C) and fifth (A to T) positions from the 5′ end. Other primers were designed using Primer Explorer V5 software (Table 3).

### LAMP

The LAMP reaction mixture (25 μL) contained 1.6 μM FIP and BIP each, 0.2 μM F3 and B3 each, 0.4 μM LF, 8 U Bst DNA polymerase (large fragment) (New England

### TABLE 2 | Clinical Pseudomonas aeruginosa isolates evaluated.

| Strain no. | Origin of isolate | Genotype | Meropenem MIC (mg/L) | PCR | GES-LAMP | Carba-GES-LAMP |
|------------|------------------|----------|----------------------|-----|----------|----------------|
| GES-β-lactamase-producing strains |
| AZPAE14831 | Argentina RTI² | GES-1 | 0.5 (S)² | (+) | (+) | (-) |
| AZPAE14948 | Argentina IA³ | GES-5 | >32 (R) | (+) | (+) | (+) |
| AZPAE13856 | India Unknown | GES-7 | 0.5 (S) | (+) | (+) | (-) |
| AZPAE13848 | India Unknown | GES-9 | 0.25 (S) | (+) | (+) | (-) |
| AZPAE13890 | Mexico Unknown | OXA-2, GES-19, GES-20-like | >32 (R) | (+) | (+) | (+) |
| Other β-lactamase-producing strains |
| AZPAE13872 | Mexico Unknown | IMP-15 | >32 (R) | (-) | (-) | (-) |
| AZPAE13879 | Argentina Unknown | VIM-11, OXA-17 | 16 (R) | (-) | (-) | (-) |
| AZPAE14688 | Mexico Unknown | IMP-18 | >32 (R) | (-) | (-) | (-) |
| AZPAE14719 | Colombia RTI | KPC-2 | >32 (R) | (-) | (-) | (-) |
| AZPAE14720 | Colombia UTI³ | OXA-2, KPC-2 | >32 (R) | (-) | (-) | (-) |
| AZPAE14822 | Brazil IA¹ | OXA-66 | 8 (R) | (-) | (-) | (-) |
| AZPAE14862 | India UTI | IMP-13 | 2 (S) | (-) | (-) | (-) |
| AZPAE14900 | India IA¹ | OXA-10, VEB-like, VIM-5 | 16 (R) | (-) | (-) | (-) |
| AZPAE15029 | France RTI | VIM-2, OXA-4 | >32 (R) | (-) | (-) | (-) |

| a | b | c |
|---|---|---|
| Respiratory tract infections; | Urinary tract infections, | Intra-abdominal infections. |
| a | b | c |
| β-lactamase-producing strains | β-lactamase-producing strains | Other β-lactamase-producing strains |
| a | b | c |
| Table 2 | Table 3 | Table 3 |

### TABLE 3 | LAMP primer sets used for genotypic identification of blaGES and the single missense mutation (G493A) that changes glycine 165 to a serine, endowing the enzyme with carbapenemase activity.

| Primer set | Sequence 5′-3′ |
|------------|----------------|
| GES-LAMP primer | ACC ATT GAG AGG TGG TCG AT |
| GES-F3 | TCA CGA ACA GAG GCA ACT |
| GES-B3 | GGT GGC GCA GGT ACC AGT TTT CCG |
| GES_FIP | ACA CTA CGA GCG GGT T |
| GES_BIP | GCC CAG GAG AGA GAT TAC GCT GAT TCG TCA GGT TCT ACG GC |
| GES_LF | TCT CCA ACA ACC CAA TCT TTA GG |
| GES_LB | GTG TAT ACA ACC GCG CCG A |
| Carba-GES-LAMP primer | TGC AGC TTA GCG ACA ATG G |
| Carba-GES_F3 | CGG CCA TAG AGG ACT TTA GC |
| Carba-GES_B3 | AGC CGA CTC ACA GAG TGG CCA GAG |
| Carba-GES_FIP | AAA TTG GGC GAG CTG |
| Carba-GES_BIP | AAGCCTCAGATCACTGGCGGAG |
| Carba-GES_LF | ACA GCA ATG GAG GCA A |
| Carba-GES_LB | CGA AAA TAC TGC GTC ATT GCA A |
| Carba-GES-LF | CCT CAG AGA TAC AAG TAC GCC TA |

| a | b | c |
|---|---|---|
| A single missense mutation (G493A) detected by ARMS; | Original sequence G; | Original sequence A. |
BIOLABS, Ipswich, MA, United States), 1.4 mM all four deoxynucleoside triphosphates, 0.8 M betaine (Sigma, St. Louis, MO, United States), 20 mM Tris–HCl (pH 8.8), 10 mM KCl, 10 mM (NH₄)₂SO₄, 8 mM MgSO₄, 0.1% (v/v) Tween 20, and template DNA (2 µL). Each mixture was incubated at 63°C for 60 min and then heated at 80°C for 2 min to terminate the reaction. For the Carba-GES-LAMP assay, the incubation time was 50 min. We monitored reaction tube turbidity in real time using a Loopamp turbidimeter (EXIA; Eiken Chemical Co., Tokyo, Japan) to read the optical density at 650 nm (OD₆₅₀) at 6-s intervals. We recorded the time required to exceed a turbidity level of 0.1, in accordance with the manufacturer’s protocol. Amplified products could be seen with the naked eye.

Analysis of LAMP Products
Amplified LAMP products were sequenced at the Akita Prefectural University Biotechnology Center using the BigDye Terminator V3.1 cycle sequencing kit (Applied Biosystems). The following F2 primers for GES-LAMP

\[ \text{GES-F, } 5' \text{′-CTA TTA CTG GCA GGC ATC G-3′} \]

and Carba-GES-LAMP were used to sequence the target regions; GES-F2, 5′-TTC TAG CAT CGG GAC ACA TG-3′ and Carba-GES-F2, 5′-AGA GAA ATT GGC GGA CCT G-3′, respectively.

PCR

blaGES genes were amplified by PCR using previously described primers: GES-F, 5′-CTA TTA CTG GCA GGC ATC G-3′; GES-R, 5′-CCT CTC AAT GGT GTG GGT-3′ (Monteiro et al., 2012). PCR assays were performed using the Ex Taq enzyme (Takara Bio, Tokyo, Japan) in a 25 µL reaction mixture containing 0.2 mM each deoxyribonucleoside triphosphate, 10 mM Tris–HCl buffer (pH 8.3), 50 mM KCl, 2 mM MgCl₂, 0.5 µM each primer, 1 U Ex Taq DNA polymerase, and template DNA (2 µL). The PCR program sequence was 94°C for 1 min, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 60 s, and a final extension at 72°C for 15 min, followed by storage at 4°C. All reactions were performed in duplicate using the Veriti thermal cycler (Applied Biosystems). The resulting PCR products were subjected to agarose gel electrophoresis followed by staining with ethidium bromide. The expected size of the DNA fragment is 594 bp.

DNA-Spiked Specimens

To analyze the effects of biological substances on the established LAMP amplification, we studied the sensitivity of the LAMP assay using DNA-spiked clinical samples. We collected urine and blood specimens from five healthy volunteers in Nihon University School of Medicine. The blood specimens were heparinised and stored at −80°C. Sputum specimens were obtained from seven patients of the Ageo Central General Hospital and frozen at −80°C to inactivate bacteria. After approval was granted by the Biosafety Committee of Nihon University, the specimens were handled using the risk group 2 protocol of the laboratory biosafety manual of the World Health Organization, Geneva, 2004 (World Health Organization, 2004).

Urine specimens were boiled at 95°C for 5 min and then centrifuged at 1,500 rpm. Blood and sputum samples were subjected to a Loopamp™ PURE DNA extraction kit (Eiken Chemical Co.) according to the manufacturer’s instructions. Purified blaGES DNA (from P. aeruginosa ARC3917) was spiked into the specimens and used to determine the detection limits of the GES-LAMP and PCR assays.

Ethics Statement

We utilized urine and blood specimens from five healthy volunteers in Nihon University School of Medicine. The study protocol was reviewed and approved by the Institutional Review Board of Nihon University School of Medicine (IRB # 28-9-0). Written informed consent was obtained from five healthy volunteers. Using the IRB approved protocol, seven patient sputum specimens (Ageo Central General Hospital) were collected in accordance with the recommendations of the Japan Society of Clinical Examination Medicine that supports “the use of specimens that have completed clinical tests for work, education, research.” This guidance provides access to specimens when it is difficult to obtain consent, the sample is anonymized, and where the scientific/ethical review committee (i.e., IRB) has approved the study protocol. Written consent was waived because specimens were anonymized discarded samples from the hospital clinical laboratory. The ethical approval for collection of those specimens were obtained from the ethical committee at the Ageo Central General Hospital (Approval # 434) and the Institutional Review Board of Nihon University School of Medicine (Approval # 28-9-0).

RESULTS

Analytical Reactivity and Specificity of the GES-LAMP Assay

The LAMP assay successfully amplified the target sequence, as confirmed by visually evident turbidity in the reaction tube and by real-time turbidimetry (Figure 1). Of the various β-lactamase genes, the assay detected only blaGES (Table 1). The product was subjected to direct sequencing. The sequences were compared with those of the targeted region (bases 337–425) of the GES-1 gene (from F1 to B1c, Supplementary Figure S1A). The sequences obtained were identical to those expected (Supplementary Figure S2A).

Detection Limits

The detection limit of the GES-LAMP assay was 10 DNA copies per reaction, and that of the PCR assay was 100 copies. The LAMP assay was thus highly sensitive, 10-fold more so than PCR. LAMP products were measurable turbidimetrically in real-time and were evident with the naked eye. No false-positive reactions were observed.

DNA-Spiked Specimens

Assay detection limits were determined using DNA-spiked blood, urine, and sputum. The GES-LAMP detection limits were 10 DNA copies per reaction, thus identical to that reported above (Table 4). The PCR detection limits were 100 DNA copies for the
FIGURE 1 | \( \text{bla}_{ \text{GES} } \) LAMP assay data derived via real-time turbidimetry. Serial 10-fold-diluted samples (10\(^5\), 10\(^4\), 10\(^3\), 10\(^2\), 10, and 1 DNA copies) were assayed by LAMP. The detection limit was 10 DNA copies.

DNA-spiked urine and sputum specimens, again identical to that reported above. However, the detection limit was >10\(^5\) copies in DNA-spiked blood specimens (Table 4).

**Evaluation Using Clinical Strains**

Using the 14 clinical \( P. \text{aeruginosa} \) strains, the GES-LAMP assay amplified the five \( \text{bla}_{ \text{GES} } \) segments (GES-1, -5, -7, -9, and -19/20-like; Table 2), and no other genotype. The results were thus identical to those of PCR (Table 2 and Supplementary Figure S3).

**Carba-GES-LAMP Assay**

Of the five \( \text{bla}_{ \text{GES} } \)-positive samples, only GES-5 and -19/20-like \( \beta\)-lactamase-producing isolates exhibited carbapenem resistance (Table 2), consistent with their genotypes. Our Carba-GES-LAMP assay detected only GES-5 and -19/20-like alleles containing the \( \text{bla}_{ \text{GES} } \) Gly165Ser missense mutation. Using the ARMS, we successfully designed the Carba-GES-LAMP primers that distinguish the GES variants. The detection limit of the Carba-GES-LAMP assay was 10\(^4\) DNA copies. No amplification of non-carbapenemase-producing \( \text{bla}_{ \text{GES} } \) genotypes (GES-1, -7, and -9) or any other genotype was evident within 50 min. The product was subjected to direct sequencing. The sequences were compared with those of the targeted region (bases 450–512) of the GES-5 gene (from F1 to B1c, Supplementary Figure S1B). The five base pairs of 3′ end of B1c region were matching to the Carba-GES-LAMP primer sequences (ACGTC; 493-497, Supplementary Figure S1B) including two mutations (Table 3) and obtained other sequences were identical to those expected (Supplementary Figure S2B).

**DISCUSSION**

We established a novel LAMP assay detecting \( \text{bla}_{ \text{GES} } \). Because \( \beta\)-lactamase genes spread widely via plasmids, rapid and accurate POCT drug-resistance assessment is imperative. Our \( \text{bla}_{ \text{GES} } \) LAMP assay was highly specific and more sensitive than PCR. \( \text{bla}_{ \text{GES} } \) was correctly identified in 14 clinical isolates expressing various \( \beta\)-lactamases. LAMP reactions are not inhibited by contaminants in DNA-spiked samples. On the other hand, PCR reactions are inhibited by such contaminants, especially heparin (Satsangi et al., 1994), and other blood components including heme, leukocyte DNA, and immunoglobulin G; such inhibitors must be removed prior to PCR (Al-Soud et al., 2000; Al-Soud and Radstrom, 2001). We used the Loopamp\textsuperscript{TM} PURE DNA extraction kit (Eiken Chemical Co.) to extract DNA over 30 min, and centrifugation was not required. LAMP can thus be performed at the bedside. We then sought to detect the G493A mutation. GES \( \beta\)-lactamases hydrolyse oxyiminocephalosporins and those with the Gly165Ser mutation exhibit carbapenemase activity (Naas et al., 2016). \( P. \text{aeruginosa} \) \( \text{bla}_{ \text{GES} } \) strains may cause fatal nosocomial diseases. An outbreak of GES-5 \( \beta\)-lactamase-producing \( P. \text{aeruginosa} \) was reported in a long-term Japanese care facility (Kanayama et al., 2016). We designed GES-type carbapenemase-specific primers via

| TABLE 4 | Detection limits of the PCR and LAMP assays used to detect DNA from \( P. \text{aeruginosa} \) of genotype \( \text{bla}_{ \text{GES} } \) in DNA-spiked specimens. |
|-----------|------------------|
| Detection limit |
| **PCR** | **GES-LAMP** |
| Purified DNA | 10\(^2\) copies\(^a\) | 10 |
| DNA spiked specimens | | |
| Urine\(^b\) | 10\(^2\) | 10 |
| Sputum\(^c\) | 10\(^2\) | 10 |
| Blood\(^d\) | >10\(^5\) | 10 |

\(^a\)Amount of DNA per reaction; \(^b\)Supernatant data obtained after boiling and centrifugation; \(^c\)Samples prepared via Loopamp\textsuperscript{TM} PURE DNA extraction kit (Eiken Chemical Co.).
ARMS, first demonstrated in 1989 (Newton et al., 1989) to detect any mutation via PCR. In 2007, Ikeda et al. used ARMS to design LAMP primers and detected a point mutation predicting the effects of the anti-lung cancer drug gefitinib (Ikeda et al., 2007). We previously used ARMS to establish a LAMP assay that distinguished Neisseria meningitidis serogroup Y from serogroup W (Lee et al., 2015). Here, we used ARMS to design the BIP, avoiding amplification of the wild-type gene. LAMP may be useful to detect GES-type carbapenemase genes.

CONCLUSION

We established a novel LAMP assay for blaces with a comparable specificity and greater sensitivity to those of PCR. LAMP assays do not require substrate purification and are appropriate for POCT. LAMP can be used to detect GES-type carbapenemase genes with missense mutations. Further work involving more clinical specimens is required.

AUTHOR CONTRIBUTIONS

CT, MS, DK, HG, RM, KK, and PK contributed the conception of this study. CT and MS designed the experiments. HG, RM, KK, and PK acquired the samples. CT and MS analyzed the data. CT, MS, DK, and SH interpreted the data, drafted the manuscript, and approved the manuscript.

REFERENCES

Al-Soud, W. A., Jonsson, L. J., and Radstrom, P. (2000). Identification and characterization of immunoglobulin G in blood as a major inhibitor of diagnostic PCR. J. Clin. Microbiol. 38, 345–350.

Al-Soud, W. A., and Radstrom, P. (2001). Purification and characterization of PCR-inhibitory components in blood cells. J. Clin. Microbiol. 39, 485–493. doi: 10.1128/JCM.39.2.485–493.2001

Bebrone, C., Bogaerts, P., Delbruck, H., Bennink, S., Kupfer, M. B., Rezende de Castro, R., et al. (2013). GES-18, a new carbapenem-hydrolyzing GES-Type beta-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues. Antimicrob. Agents Chemother. 57, 396–401. doi: 10.1128/AAC.01784-12

Bonnin, R. A., Jouisset, A. B., Urvo, N., Gauthier, L., Tlili, L., Creton, E., et al. (2017). Detection of GES-5 carbapenemase in Klebsiella pneumoniae, a newcomer in France. Antimicrob. Agents Chemother. 61, e2263–e2216. doi: 10.1128/AAC.00226-13

Bratu, S., Landman, D., Alam, M., Tolentino, E., and Quale, J. (2005). Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother. 49, 776–778. doi: 10.1128/AAC.02277-2005

Clinical Laboratory Standards and Institute. (2012). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-two Informational Supplement. Vol.32.M100-S22. Wayne, PA: CLSI.

de Oliveira, D. V., Nunes, L. S., Barth, A. L., and Van Der Sand, S. T. (2017). Genetic background of beta-Lactamases in Enterobacteriaceae isolates from environmental samples. Microb. Ecol. 74, 599–607. doi: 10.1007/s00248-017-0970-6

FUJITSU, L. (2016). PrimerExplorer V5 [Online]. Available at: http://primerexplorer.jp/e

Ikeda, S., Takabe, K., Inagaki, M., Funakoshi, N., and Suzuki, K. (2007). Detection of gene point mutation in paraffin sections using in situ loop-mediated isothermal amplification. Pathol. Int. 57, 594–599. doi: 10.1111/j.1440-1827.2007.02144.x

Kanayama, A., Kawahara, R., Yamagishi, T., Goto, K., Kobaru, Y., Takano, M., et al. (2016). Successful control of an outbreak of GES-5 extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa in a long-term care facility in Japan. J. Hosp. Infect. 93, 35–41. doi: 10.1016/j.jhin.2015.12.017

Kos, V. N., Deraspe, M., McLaughlin, R. E., Whiteaker, J. D., Roy, P. H., Alam, R. A., et al. (2015). The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob. Agents Chemother. 59, 427–436. doi: 10.1128/AAC.03954-14

Lee, D., Kim, E. I., Kilgore, P. E., Takahashi, H., Ohnishi, M., Tomono, J., et al. (2015). A novel loop-mediated isothermal amplification assay for serogroup identification of Neisseria meningitidis in cerebrospinal fluid. Front. Microbiol. 6:1548. doi: 10.3389/fmicb.2015.01548

Miyoshi-Akiyama, T., Tada, T., Ohmagari, N., Viet Hung, N., Tharavichitkul, P., Pokhrel, B. M., et al. (2017). Emergence and spread of epidemic multidrug-resistant Pseudomonas aeruginosa. Genome Biol. Evol. 9, 3238–3245. doi: 10.1093/gbe/evx243

Monteiro, J., Widen, R. H., Pignataro, A. C., Kubasek, C., and Silbert, S. (2012). Rapid detection of carbapenemase genes by multiplex real-time PCR. J. Antimicrob. Chemother. 67, 906–909. doi: 10.1093/jac/dkr563

Naas, T., Dortet, L., and Iorga, B. I. (2016). Structural and functional aspects of class a carbapenemases. Curr. Drug Targets 17, 1006–1028. doi: 10.2174/1389450117666160310144501

Newton, C. R., Graham, A., Heptinstall, L. E., Powell, S. J., Summers, C., Kalsheker, N., et al. (1989). Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17, 2503–2516. doi: 10.1093/nar/17.7.2503

Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., et al. (2000). Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 28:E63. doi: 10.1093/nar/28.12.e63

Poirel, L., Bonnin, R. A., and Nordmann, P. (2012). Genetic support and diversity of acquired extended-spectrum beta-lactamasen in Gram-negative rods. Infect. Genet. Evol. 12, 883–893. doi: 10.1016/j.meegid.2012.02.008

Poirel, L., Le Thomas, I., Naas, T., Karim, A., and Nordmann, P. (2000). Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase.

FUNDING

This study was supported by JSPS Bilateral Open Partnership Joint Research Projects (MS). DK was supported by the grants NRF-2018R1A2A2A05018341 and NRF-2015M3C9A2054024 from National Research Foundation (NRF) of South Korea.

ACKNOWLEDGMENTS

We thank all staff of Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2019.00025/full#supplementary-material
beta-lactamase, and the class 1 integron In52 from *Klebsiella pneumoniae*. 
*Antimicrob. Agents Chemother.* 44, 622–632. doi: 10.1128/AAC.44.3.622-632, 2000

Satsangi, J., Jewell, D. P., Welsh, K., Bunce, M., and Bell, J. I. (1994). Effect of heparin on polymerase chain reaction. *Lancet* 343, 1509–1510. doi: 10.1016/S0140-6736(94)92622-0

World Health Organization (2004). *Laboratory Biosafety Manual* – 3rd Edn. Available at: http://www.who.int/csr/resources/publications/biosafety/WHO_CDS_CSR_LYO_2004_11/en/

Yamasaki, K., Komatsu, M., Ono, T., Nishio, H., Sueyoshi, N., Kida, K., et al. (2017). Nosocomial spread of *Klebsiella pneumoniae* isolates producing blaGES-4 carbapenemase at a Japanese hospital. *J. Infect. Chemother.* 23, 40–44. doi: 10.1016/j.jiac.2016.09.006

**Conflict of Interest Statement:** HG is an employee of Evelo Biosciences.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Takano, Seki, Kim, Gardner, McLaughlin, Kilgore, Kamisaka and Hayakawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.